SEATTLE, WA / ACCESSWIRE / May 18, 2021 / EMulate Therapeutics Inc, a clinical-stage therapeutic device company, announced today a corporate update.
Featured in a Healthcare Tech Outlook article, titled “Ushering in a New Era in Non-Invasive Cancer Therapy,” featured in Healthcare Tech Outlook.
Additional areas of application targeted include chronic pain, mental health and continued growth in company’s oncology franchise
EMulate Therapeutics’ CEO, Chris Rivera commented, “It is very satisfying that EMulate’s platform technology has enabled EMulate to be recognized as one of the Top 10 Digital Health providers. Our magnetic field technology has proven to emulate the effects of drug therapy without the actual chemical being ingested, and development of the technology has made substantial progress, especially in the areas of Cancer, Pain and CNS / Mental Health. Additionally, we continue to advance our pipeline capability, notably in the areas of Animal Health, Agriculture Biotechnology and in non-medical uses available through EMulate’s licensee, Hapbee Technologies, Inc.”
Recent Highlights and Upcoming Milestones
EMulate Pain Relief:
EMulate CNS / Mental Health:
EMulate Oncology:
EMulate Animal Health, Agriculture and Industrial Biotech:
Mr. Rivera added, “Internally, we continue to focus on signal enhancement, including increasing effect and predictability. The data that the company has generated to date with current signals is very important; however, to optimize shareholder value, we must be able to perfect our understanding of how the signals work. We are partnered with Hapbee Technologies, Inc. and other stakeholders to generate stronger, more effective and predictable signals for consumers, patients, animals and all future users. We believe that we are well on our way to a successful path forward and will make significant progress by year’s end.”
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical-stage therapeutic device company that makes targeted, non-invasive, safe, and effective treatment a reality. The company’s groundbreaking technology has the potential to treat cancer and various other diseases without chemicals, radiation, or drugs and with minimal or no adverse effects. The technology is based on magnetically-induced changes to cellular function to produce a therapeutic response. It uses precisely targeted, ultra-low radiofrequency energy delivered via non-invasive devices, such as the EMulate Therapeutics Voyager and Hӕlo®, to specifically regulate signaling and metabolic pathways on the molecular and genetic levels. To learn more, please visit https://emulatetx.com/
Company Contact:
David Matteson
dmatteson@emultatetx.com
Cell: 425/478-2121
Investor Contact:
James Carbonara
Hayden IR
Tel (646) 755-7412
james@haydenir.com
SOURCE: EMulate Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/647551/EMulate-Therapeutics-Named-Top-10-Digital-Health-Provider-by-Healthcare-Tech-Outlook-Magazine–Provides-Corporate-Update–Magnetic-Field-Therapies-for-Pain-to-Yield-Pre-Clinical-Data-in-June-CNS-Mental-Health-models-including-PTSD-and-Anxiety-to
Real-World testing nanotechnology to provide insights for manufacturing process with DunmoreOakville, Ontario--(Newsfile Corp. - July…
CordenPharma is making a record investment of ~€900m over the next 3 years in expanding…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI), a global leader in noninvasive…
Henry Charlton and Claire Poulard to join the Board of Directors Funding will Accelerate US…
NEW YORK, July 15, 2024 /PRNewswire/ -- The global trenbolone enanthate market size is estimated to grow by…
NEW YORK, July 15, 2024 /PRNewswire/ -- The global mindfulness meditation application market size is…